ncRNA name
CASC2
Specific or universal ncRNAs
Universal ncRNAs
Class
Long noncoding RNA
Biomarker
Yes
Biomarker application
Treatment
Upstream regulatory factors
Not available
Downstream target
miR-18a-5p/CDK19
Cancer name
Breast Cancer
Cancer site
Breast
Treatment type
Chemotherapy
Drug
Paclitaxel
Impact of wild-type ncRNA on chemotherapy resistance
Up
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
We identified that CASC2 activated PTX resistance in breast cancer through regulation of miR-18a-5p/CDK19.
Tissue resource
paclitaxel-resistant breast cancer tissue and paclitaxel-sensitive breast cancer tissue
human breast cancer cell lines MCF-7
human breast cancer cell lines MDA-MB-231
normal breast cell lines MCF-10A
Experiment
qRT-PCR,Western blot
Institute
the First Affiliated Hospital of Xinxiang Medical University
Chinese Academy of Sciences
Country
China
Continent
Asia